Category Archives: HIV care & treatment

Seeking your help to end the HIV and hepatitis C epidemics and significantly reduce the incidence of STDs in California!

Project Inform is partnering with HIV, hepatitis and STD organizations from across the state to call on the next Governor of California to develop and implement a statewide plan to end the HIV and hepatitis C epidemics and to significantly reduce the incidence of STDs. We…Read More

IAS2018: Zero transmissions mean zero risk – PARTNER 2 study results announced

Reported by and re-posted from We’re as confident now that undetectable gay men pose no risk of HIV transmission as we already were for heterosexuals, researchers say The chance of any HIV-positive person with an undetectable viral load transmitting the virus to a sexual partner…Read More

IAS2018: Bay Area, U.S. & GlobaRights Advocates Demand 2020 International AIDS Conference Be Removed from U.S.

Re-posted from Positive Women’s Network **FOR IMMEDIATE RELEASE** Contact: Cecilia Chung +1.415.902.0216, Naina Khanna +1.510.681.1169, George Ayala +, BAY AREA, U.S. AND GLOBAL HUMAN RIGHTS ADVOCATES DEMAND 2020 INTERNATIONAL AIDS CONFERENCE BE REMOVED FROM U.S. They cite danger for potential participants and human…Read More

IAS2018: Communique of the Kigali Dolutegravir Stakeholder Meeting of African Women Living with HIV, hosted by AfroCAB

We, the thirty-nine women living with HIV representing 18 countries, met in Kigali on July 13 and 14 to discuss the potential neural tube defect (NTD) safety signal in women taking dolutegravir (DTG) at conception and develop a joint position on behalf of women for access…Read More

FDA approves new single tablet regimen Symtuza for treating chronic HIV infection

On July 17, 2018, the Food and Drug Administration approved a new single tablet regimen (STR) for treating chronic HIV, called Symtuza. The once-a-day, full-regimen pill contains four drugs: the protease inhibitor darunavir (Prezista) + the booster cobicistat (Tybost) + the NRTIs emtricitabine (FTC/Emtriva) and tenofovir…Read More

Statement on Potential Safety Signal in Infants Born to Women Taking Dolutegravir from the HHS Antiretroviral Guideline Panels

Date: May 18, 2018, reprinted from AIDSinfo The HHS Antiretroviral Guidelines Panels1 are issuing this statement in response to a potential safety signal in infants born to women who were taking dolutegravir (DTG)-based antiretroviral (ARV) drug regimens at the time of conception in accordance with guidance…Read More

New HIV medication ibalizumab (Trogarzo) approved by the FDA for people with few treatment options

On March 6, 2018, the FDA approved a new type of HIV medication called ibalizumab for people who have few to no treatment options due to multi-drug resistant virus. The approval was based on results from the TMB-301 study that showed that adding the drug to…Read More